Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics
Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis. Accurate diagnosis of these tumors is dependent on the identification of underlying genetic aberrations, which can include large, and often complex, structural variants (SVs) or copy number variants (CNVs) involving oncogenes or tumor suppressor genes. The detection of SVs and CNVs remains challenging and typically requires multiple traditional cytogenetic techniques. In this study, researchers demonstrated OGM’s ability to detect aberrations as small as 500 bp, which is approximately 10,000-fold higher resolution than that of KT. As shown in this study, OGM can provide better characterization of the genomic complexity of sarcoma samples when compared to traditional cytogenetic techniques, due to the workflow’s high resolution and comprehensive, genome-wide analysis.
Key findings:
- OGM was concordant with traditional methods for the detection of pathogenic variants in 32 out of 35 cases (91%)
- OGM detected loss of CDKN2A/B in 9 out of 38 cases (24%), all missed by classical methods, which is associated with poor prognosis in soft tissue sarcomas
- OGM uniquely detected chromothripsis in 9 out of 35 cases (26%)
- In 5 out of 25 cases (20%) with diagnostic fusions, OGM showed that chains of rearrangements generated the fusions, three of which involved chromoplexy
“Characterization of sarcoma is enormously challenging and requires several different techniques, which often yield equivocal results that don’t explain the underlying disorder. We are pleased to see results from this study on the use of OGM to investigate sarcomas, which provided the study authors with insights into the genomic complexity underlying various aberrations, highlighting the high sensitivity and robustness of our workflow and enhancing our understanding of tumor biology. We believe this study is an important advancement for OGM and for the cancer research community as it now illustrates the utility of OGM not only in cancer, but in an important solid tumor,” commented
The publication can be viewed here.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Unless specifically noted otherwise, Bionano’s OGM products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “can,” “may” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances and the negatives thereof) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability of OGM to detect aberrations as small as 500 bp; the potential of OGM to deliver concordant results with traditional cytogenetic methods; the ability of OGM to uniquely identify SVs when comparted to traditional cytogenetic methods; the ability of OGM to detect pathogenically relevant SVs in sarcomas; the future potential for OGM to provide improved diagnoses of sarcomas when compared to traditional cytogenetic techniques; and other statements that are not historical facts.
Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of geopolitical and macroeconomic developments, such as recent and future bank failures, the ongoing conflicts between
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
+1 (858) 888-7625
IR@bionano.com
Source: Bionano Genomics